A Phase II study of YY003 in adults with moderate-to-severe glabellar lines has been completed.
We pair regional innovation with focused execution across clinical development, regulatory strategy and CMC.
Our lead program, YY003, is an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation.
Revelyx Bio is built to advance Asia-Pacific innovation into the world's largest markets.
Revelyx pairs regional innovation with focused execution across clinical development, regulatory strategy and CMC.
​Our lead program, YY003, is an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation.
A Phase II study of YY003 in adults with moderate-to-severe glabellar lines has been completed
Our lead program, YY003, is an investigational recombinant botulinum toxin type A (rBoNT/A) in a ready-to-use liquid formulation. In September 2026, Revelyx reported positive topline results from a Phase 2 clinical trial in adults with moderate-to-severe glabellar lines. The trial met its primary endpoints and key secondary endpoints.
Molecule
Recombinant botulinum toxin type A (rBoNT/A)
Presentation
Ready-to-use liquid in a prefilled syringe
Lead Indication
Moderate-to-severe glabellar lines
Rights
Exclusive, for development and commercialization across aesthetic and therapeutic indications
Territory
Global, excluding mainland China, Hong Kong and Macau
Licensed From
Chongqing Claruvis Pharmaceutical Co., Ltd.
Molecule
Recombinant botulinum toxin type A (rBoNT/A)
Presentation
Ready-to-use liquid in a prefilled syringe
Lead Indication
Moderate-to-severe glabellar lines
Right
Exclusive, for development and commercialization across aesthetic and therapeutic indications
Territory
Global, excluding mainland China, Hong Kong and Macau
Licensed From
Chongqing Claruvis Pharmaceutical Co., Ltd.
YY003
Molecule
Recombinant botulinum toxin type A (rBoNT/A)
Rights
Exclusive, for development and commercialization across aesthetic and therapeutic indications
Presentation
Ready-to-use liquid in a prefilled syringe
Territory
Global, excluding mainland China, Hong Kong and Macau
Lead Indication
Moderate-to-severe glabellar lines
Licensed From
Chongqing Claruvis Pharmaceutical Co., Ltd.
YYOO3
Molecule
Recombinant botulinum toxin type A (rBoNT/A)
Presentation
Ready-to-use liquid in a prefilled syringe
Lead Indication
Moderate-to-severe glabellar lines
Rights
Exclusive, for development and commercialization across aesthetic and therapeutic indications
Territory
Global, excluding mainland China, Hong Kong and Macau
Licensed From
Chongqing Claruvis Pharmaceutical Co., Ltd.
From conventional fermentation to precision genetic engineering
Traditional Production
Neurotoxin produced in cultures of Clostridium botulinum and subsequently purified
Botulinum toxin type A produced through recombinant expression in E. coli
Recombinant Production
Molecule
Recombinant botulinum toxin type A (rBoNT/A)
Presentation
Ready-to-use liquid in a prefilled syringe
Lead Indication
Moderate-to-severe glabellar lines
Rights
Exclusive, for development and commercialization across aesthetic and therapeutic indications
Territory
Global, excluding mainland China, Hong Kong and Macau
Licensed From
Chongqing Claruvis Pharmaceutical Co., Ltd.
Most botulinum toxin products are produced by growing Clostridium botulinum and purifying the resulting neurotoxin.
The neurotoxin is produced through recombinant expression in E. coli, a method widely used across biologic medicines. The process is designed to provide control over the identity and purification of the expressed neurotoxin.
YY003 builds on Claruvis's recombinant platform, which also underpins Retoxin® (YY001). Retoxin received marketing approval from China's National Medical Products Administration in March 2026 as the world's first approved recombinant botulinum toxin type A.
YY003 takes a different approach
IND Cleared
U.S. Food and Drug Administration · September 2024
Phase II Completed
Randomized, double-blind,
vehicle-controlled study in adults with moderate-to-severe glabellar lines in Australia · NCT06481475
IND Cleared
U.S. Food and Drug Administration
September 2024
Phase II Completed
Randomized, double-blind,
vehicle-controlled study in adults with moderate-to-severe glabellar lines in Australia · NCT06481475
Dustin Sjuts
Chief Executive Officer
Chief Executive Officer
Dustin Sjuts
Dustin Sjuts brings more than 20 years of experience advancing injectable biologics from clinical development through manufacturing and commercialization. Previously, as President of Revance Therapeutics, he led the company's commercial, clinical, regulatory and technical operations through two FDA approvals and U.S. commercial launches of a novel neuromodulator. Earlier, he led Galderma's aesthetics business in Greater China and held commercial leadership roles at Allergan.
August 31, 2026